183 related articles for article (PubMed ID: 27756228)
21. Cancer in silico drug discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypes.
San Lucas FA; Fowler J; Chang K; Kopetz S; Vilar E; Scheet P
Mol Cancer Ther; 2014 Dec; 13(12):3230-40. PubMed ID: 25349306
[TBL] [Abstract][Full Text] [Related]
22. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
23. Pericytes Promote Malignant Ovarian Cancer Progression in Mice and Predict Poor Prognosis in Serous Ovarian Cancer Patients.
Sinha D; Chong L; George J; Schlüter H; Mönchgesang S; Mills S; Li J; Parish C; Bowtell D; Kaur P;
Clin Cancer Res; 2016 Apr; 22(7):1813-24. PubMed ID: 26589433
[TBL] [Abstract][Full Text] [Related]
24. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
[TBL] [Abstract][Full Text] [Related]
25. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
[TBL] [Abstract][Full Text] [Related]
27. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
[TBL] [Abstract][Full Text] [Related]
28. Gene-Set Local Hierarchical Clustering (GSLHC)--A Gene Set-Based Approach for Characterizing Bioactive Compounds in Terms of Biological Functional Groups.
Chung FH; Jin ZH; Hsu TT; Hsu CL; Liu HC; Lee HC
PLoS One; 2015; 10(10):e0139889. PubMed ID: 26473729
[TBL] [Abstract][Full Text] [Related]
29. Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun.
Itamochi H; Oishi T; Shimada M; Sato S; Uegaki K; Naniwa J; Sato S; Nonaka M; Terakawa N; Kigawa J; Harada T
Clin Cancer Res; 2011 Jul; 17(14):4742-50. PubMed ID: 21610153
[TBL] [Abstract][Full Text] [Related]
30. Strong cytotoxic effect of the bradykinin antagonist BKM-570 in ovarian cancer cells--analysis of the molecular mechanisms of its antiproliferative action.
Jutras S; Bachvarova M; Keita M; Bascands JL; Mes-Masson AM; Stewart JM; Gera L; Bachvarov D
FEBS J; 2010 Dec; 277(24):5146-60. PubMed ID: 21078129
[TBL] [Abstract][Full Text] [Related]
31. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
Ponte JF; Ab O; Lanieri L; Lee J; Coccia J; Bartle LM; Themeles M; Zhou Y; Pinkas J; Ruiz-Soto R
Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
[TBL] [Abstract][Full Text] [Related]
32. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
33. In-silico drug screening and potential target identification for hepatocellular carcinoma using Support Vector Machines based on drug screening result.
Yang WL; Lee YE; Chen MH; Chao KM; Huang CY
Gene; 2013 Apr; 518(1):201-8. PubMed ID: 23220021
[TBL] [Abstract][Full Text] [Related]
34. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.
Bali A; O'Brien PM; Edwards LS; Sutherland RL; Hacker NF; Henshall SM
Clin Cancer Res; 2004 Aug; 10(15):5168-77. PubMed ID: 15297421
[TBL] [Abstract][Full Text] [Related]
35. New drug candidates for treatment of atypical meningiomas: An integrated approach using gene expression signatures for drug repurposing.
Zador Z; King AT; Geifman N
PLoS One; 2018; 13(3):e0194701. PubMed ID: 29558515
[TBL] [Abstract][Full Text] [Related]
36. Connectivity mapping using a combined gene signature from multiple colorectal cancer datasets identified candidate drugs including existing chemotherapies.
Wen Q; O'Reilly P; Dunne PD; Lawler M; Van Schaeybroeck S; Salto-Tellez M; Hamilton P; Zhang SD
BMC Syst Biol; 2015; 9 Suppl 5(Suppl 5):S4. PubMed ID: 26356760
[TBL] [Abstract][Full Text] [Related]
37. Network-based survival analysis reveals subnetwork signatures for predicting outcomes of ovarian cancer treatment.
Zhang W; Ota T; Shridhar V; Chien J; Wu B; Kuang R
PLoS Comput Biol; 2013; 9(3):e1002975. PubMed ID: 23555212
[TBL] [Abstract][Full Text] [Related]
38. A tool for discovering drug sensitivity and gene expression associations in cancer cells.
Qin Y; Conley AP; Grimm EA; Roszik J
PLoS One; 2017; 12(4):e0176763. PubMed ID: 28453553
[TBL] [Abstract][Full Text] [Related]
39. DeSigN: connecting gene expression with therapeutics for drug repurposing and development.
Lee BK; Tiong KH; Chang JK; Liew CS; Abdul Rahman ZA; Tan AC; Khang TF; Cheong SC
BMC Genomics; 2017 Jan; 18(Suppl 1):934. PubMed ID: 28198666
[TBL] [Abstract][Full Text] [Related]
40. Biomarker identification for statin sensitivity of cancer cell lines.
Raghu VK; Beckwitt CH; Warita K; Wells A; Benos PV; Oltvai ZN
Biochem Biophys Res Commun; 2018 Jan; 495(1):659-665. PubMed ID: 29146185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
